Standardising drug allergy management

Minimum standards for drug allergy de-labelling

The National Allergy Strategy is developing minimum standards for drug allergy de-labelling or confirmation of drug allergy.

Many people are considered to be allergic to one or more drugs, most commonly antibiotics, usually because they have had adverse symptoms or a reaction whilst taking the drug. In some cases, this is valid, and the drug should be avoided. However, in many cases the person is not truly allergic because the symptoms were not actually caused by the drug, but rather the illness they had at the time (e.g. virus). Furthermore, the perception of allergy might be based on childhood reactions that are no longer relevant, or on entirely spurious information (e.g. the wrong drug, or a family member with allergy).

Confirmation or clarification of drug allergy reduces costs by allowing basic, safe and cheaper drugs (particularly antibiotics) to be used in those who are not allergic, which might otherwise be avoided unnecessarily. It prevents complications, results in shorter hospital stays, reduces readmissions and reduces the rate of bacterial antimicrobial resistance (in the case of antibiotics) in the community.

Developing minimum standards will help to standardise clinical practice and optimise patient safety.

Drug Allergy Management

Drug allergy managementUntreated or poorly managed allergic diseases result in preventable morbidity and unnecessary doctor visits and hospital admissions. Optimal clinical care is essential for the diagnosis and management of allergic diseases and to ensure optimal patient outcomes.

There are several issues regarding drug allergy, particularly antibiotic allergy, that require urgent attention which will improve patient outcomes, reduce waiting times for more timely access to see an allergy specialist for individuals with more complex diagnosis or management and reduce the use of more expensive antibiotics instead of relatively inexpensive first tier antibiotics.

The National Allergy Strategy (NAS) has identified the following requirements for appropriate management of drug allergy:

  • Effective drug allergy alert processes to prevent drug allergy deaths in hospitals are urgently required.
  • Appropriate allergy testing and drug avoidance protocols to reduce unnecessary avoidance of penicillin group of antibiotics which will decrease the use of more expensive antibiotics.
  • Management of patients with drug allergy in Australia is suboptimal due to the lack of standardisation of management, including clinical documentation. This highlights an urgent need for better educational support for primary and secondary healthcare practitioners treating patients with drug allergy.
  • Data on the prevalence and clinical impact of drug allergy in Australia are sparse and national documentation of drug allergy may inform future management policies.
  • A significant number of patients are referred to clinical immunology/allergy specialists when, with the right guidance, can be managed at primary or secondary care level.
  • A national registry or drug allergy database, for patients with confirmed drug allergy will allow for a comprehensive collection of health information in regards to these cases. This data is critical to understand the extent of drug allergy in Australia, compare state and Australian data with overseas registries and deliver information for future national strategies for optimal management of drug allergy.

 The government funding will enable the scoping of drug allergy issues occurring within hospitals as well as identify areas of need regarding education for health professionals.

Content updated April 2020

National Allergy Strategy Rationale

Allergic diseases have become an increasingly important chronic disease and public health issue in Australia and other developed countries over the last two decades, contributing to increased demand for medical services, significant economic cost of care and reduced quality of life of people with allergic diseases and their carers.

Information Partner

healthdirect: 
trusted health information
Funded by the governments of Australia

COVID-19 Symptom Checker

National Allergy Strategy Websites and Courses

All about Allergens
All about Allergens
The next step for cooks and chefs
The next step for cooks and chefs
Authorised Officers Resources
All about Allergens AO
Food allergy prevention
e-training for health professionals
Food allergy prevention e-training for health professionals
Paediatric atopic dermatitis
e-training for health professionals
Paediatric atopic dermatitis e-training for health professionals
Food Allergy Education
for the community
Food Allergy Education
Food Allergy Aware - Hub
Food Allergy Aware - Hub
250K for teens and young adults
250K
Nip Allergies in the Bub

Lead organisations

ascia logo 2018s
Australasian Society of Clinical Immunology and Allergy (ASCIA) is the leading medical organisation for allergy in Australia. 

aaa logo 2018s
Allergy & Anaphylaxis Australia (A&AA) is the leading patient support organisation for allergy in Australia. 

The National Allergy Strategy has received funding from the Australian Government Department of Health for the following projects:
Food allergy prevention | 250K Youth Project | Food service | Drug allergy | Shared Care Model

© National Allergy Strategy Aug 2015 | Contact Us | Disclaimer | Privacy | Sitemap